Premium
A phase i study of emetine hydrochloride (nsc 33669) in solid tumors
Author(s) -
Mastrangelo Michael J.,
Grage Theodor B.,
Bellet Robert E.,
Weiss Arthur J.
Publication year - 1973
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197305)31:5<1170::aid-cncr2820310520>3.0.co;2-4
Subject(s) - medicine , toxicity , myalgia , subcutaneous injection , muscle weakness , weakness , creatine kinase , dose ranging study , anesthesia , surgery , placebo , pathology , double blind , alternative medicine
A Phase I clinical trial of emetine hydrochloride (NSC‐33669) in adults with solid tumors was conducted using two time schedules: a. a single subcutaneous dose daily for 10 days, and b. a single subcutaneous injection every 4 days (q4d) for 10 doses. Thirty‐two patients were treated on the daily schedule with doses ranging from 1.0–2.0 mg/kg/day, and nine patients were treated in the q4d schedule with doses ranging from 1.2–2.2 mg/kg/dose. Toxicity was similar in both groups and consisted of pain at the injection site, muscle weakness and myalgia, elevations in creatine phosphokinase, and electrocardiographic abnormalities. Muscle weakness was the dose‐limiting toxicity. The maximum tolerable total dose was 10 mg/kg. No response was noted in 16 patients evaluated.